Search by Drug Name or NDC
NDC 63323-0413-36 Neostigmine Methylsulfate 0.5 mg/mL Details
Neostigmine Methylsulfate 0.5 mg/mL
Neostigmine Methylsulfate is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Fresenius Kabi USA, LLC. The primary component is NEOSTIGMINE METHYLSULFATE.
Product Information
| NDC | 63323-0413 |
|---|---|
| Product ID | 63323-413_3abc0611-0e8c-49f9-9678-e4b2fda3d8ed |
| Associated GPIs | 76000040202017 |
| GCN Sequence Number | 071070 |
| GCN Sequence Number Description | neostigmine methylsulfate VIAL 0.5 MG/ML INTRAVEN |
| HIC3 | J1B |
| HIC3 Description | CHOLINESTERASE INHIBITORS |
| GCN | 34758 |
| HICL Sequence Number | 001988 |
| HICL Sequence Number Description | NEOSTIGMINE METHYLSULFATE |
| Brand/Generic | Generic |
| Proprietary Name | Neostigmine Methylsulfate |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Neostigmine Methylsulfate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 0.5 |
| Active Ingredient Units | mg/mL |
| Substance Name | NEOSTIGMINE METHYLSULFATE |
| Labeler Name | Fresenius Kabi USA, LLC |
| Pharmaceutical Class | Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA203629 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 63323-0413-36 (63323041336)
| NDC Package Code | 63323-413-36 |
|---|---|
| Billing NDC | 63323041336 |
| Package | 10 VIAL, MULTI-DOSE in 1 TRAY (63323-413-36) / 10 mL in 1 VIAL, MULTI-DOSE |
| Marketing Start Date | 2015-01-08 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |